Harmony Biosciences Holdings, Inc. Announces Pricing of Public Offering of Common Stock by Selling Shareholders

Core Viewpoint - Harmony Biosciences Holdings, Inc. has announced a public offering of 8,000,000 shares of its common stock at a price of $31.00 per share, with an additional option for underwriters to purchase 1,200,000 shares [1] Group 1: Offering Details - The offering is being conducted by Marshman Fund Trust II and Valor IV Pharma Holdings, LLC, with J.P. Morgan acting as the sole book-running manager [1] - The company will not receive any proceeds from the sale of shares, as the offering is solely from selling shareholders [1] - The offering is expected to close on November 1, 2024, subject to customary closing conditions [1] Group 2: Regulatory Information - The shares are being offered under an effective shelf registration statement filed with the SEC, and the offering is made only by means of a prospectus supplement and accompanying base prospectus [2] - Preliminary and final prospectus supplements can be obtained free of charge on the SEC's website [2] Group 3: Company Overview - Harmony Biosciences is a pharmaceutical company focused on developing therapies for rare neurological diseases with unmet medical needs [4] - Established in 2017 and headquartered in Plymouth Meeting, PA, the company emphasizes innovation and empathy in its therapeutic advancements [4]